# Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

> **NCT02083250** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 70 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia in Remission
- Acute Myeloid Leukemia in Remission
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Anti-Thymocyte Globulin
- **DRUG:** Busulfan
- **DRUG:** Clofarabine
- **DRUG:** Fludarabine Phosphate
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Pharmacological Study
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT02083250
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-06
- **Primary completion:** 2021-11-12
- **Final completion:** 2021-11-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083250, "Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02083250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*